ConductScience.org, home

Trial · NCT04939844

REST - Replacing Steroids in the Transplant Ineligble

NCT04939844, Phase 2, Completed, Oslo University Hospital

3 sourcestrials-2026-11-12-0.5.0

Download JSON
Cite this record

ConductScience Library. REST - Replacing Steroids in the Transplant Ineligble. Trials, record NCT04939844. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04939844

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title
REST - Replacing Steroids in the Transplant Ineligble
NCT number
NCT04939844
Status
Completed
Phases
Phase 2
Enrollment
51 participants, actual
Lead sponsor
Oslo University Hospital
Conditions
Multiple Myeloma
Interventions
Isatuximab, bortezomib, lenalidomide, dexamethason
First posted
2021-06-25
Last updated
2025-03-20

Source ClinicalTrials.gov

Registered outcomes4

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

ListOutcomeTime frameDescription
PrimaryMRD negativity34 monthsThe proportion of patients who achieve MRD negativity measured by NGF Euroflow during and/or after 18 cycles of study treatment.
SecondaryOverall response rate30 monthsThe proportion of patients who achieve partial response (PR) or better following 18 cycles of study treatment
SecondaryProgression free survival4 yearsThe PFS rate of patients receiving 2 cycles of IVRd followed by 6 cycles of IVR, 10 cycles of IR and continuous R
SecondaryOverall survival5 yearsThe OS rate of patients receiving 2 cycles of IVRd followed by 6 cycles of IVR, 10 cycles of IR and continuous R.

Outcomes0

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

None in this release.

Results by group0

Each measurement the trial posted, group by group, in the words and numbers it posted.

None in this release.

Participant flow0

How many started, completed or left each group, period by period.

None in this release.

Adverse events0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

None in this release.

Adverse event totals0

The totals the trial posted for each group.

None in this release.

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMIDListed as
39909655DERIVED

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov
2026-11-12
ClinicalTrials.gov
Results, from AACT
2026-03-23
AACT
NIH grant links
2026-11-13
NIH RePORTER

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT04939844

GET https://conductscience.org/api/trials/v1/NCT04939844/registered